• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
European Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Trends & Forecast to 2017 - Product Image

European Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Trends & Forecast to 2017

  • ID: 2511995
  • April 2013
  • Region: Europe
  • 302 Pages
  • Markets and Markets

FEATURED COMPANIES

  • Bracco Imaging SPA
  • Cardinal Health, Inc
  • Covidien, Plc
  • Eczacibasi-Monrol
  • IBA Group
  • Nordion, Inc
  • MORE

'European Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Trends & Forecast to 2017'

Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation, used in the nuclear imaging field to diagnose and treat diseases. The European radioisotopes market was valued at $1.1 billion in 2012 and is poised to reach $1.6 billion in 2017 at a CAGR of 6.8%.

The radiopharmaceuticals market is broadly classified into two segments, namely, diagnostic and therapeutic; the former dominated with about 83% share in 2012. Radioisotopes in the diagnostic market are categorized as SPECT and PET. Technetium 99m (Tc-99m) dominated the SPECT radioisotope market in 2012, followed by Thallium–201(Tl-201), Gallium–67 (Ga-67) and Iodine-123 (I-123). SPECT is majorly used in cardiology related diagnosis; it is poised to grow at a CAGR of 7.0% from 2012 to 2017. The PET radioisotopes market is dominated by Fluoride-18 (F-18), followed by Rubidium-82 (Rb-82).

Segments in the therapeutic READ MORE >

FEATURED COMPANIES

  • Bracco Imaging SPA
  • Cardinal Health, Inc
  • Covidien, Plc
  • Eczacibasi-Monrol
  • IBA Group
  • Nordion, Inc
  • MORE

1 Introduction
1.1 Key Take-Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size
1.5.2 Market Share
1.5.3 Key Data Points From Secondary Sources
1.5.4 Key Data Points From Primary Sources
1.5.5 Assumptions

2 Executive Summary

3 Market Overview
3.1 Introduction
3.2 Definition Of Radiopharmaceuticals
3.3 Evolution
3.4 Market Segmentation
3.4.1 Radiopharmaceuticals
3.4.2 Stable Isotopes
3.5 Market Dynamics
3.5.1 Drivers
3.5.1.1 Increasing Incidence Of Cancer And Cardiac Ailments Boosts The Demand For Radiopharmaceuticals
3.5.1.2 Increasing Use Of Spect And Pet Scans Results In Rise Of Radiopharmaceutical Usage
3.5.1.3 Rising Awareness Of Radiopharmaceuticals To Spur Growth
3.5.1.4 Ready Availability Of Radiopharmaceuticals From Cyclotrons To Goad The Growth
3.5.2 Restraints
3.5.2.1 Shorter Half-Life Of Radiopharmaceuticals Restricts The Usage
3.5.2.2 High Capital To Limit The Buying Of Scanners
3.5.2.3 Stringent Regulatory Guidelines And Gmp To Negatively Impact Growth
3.5.2.4 Competition From Conventional Diagnostic Procedures
3.5.3 Opportunities
3.5.3.1 Potential Radioisotopes In The Pipeline
3.5.3.2 Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
3.5.3.3 Alternative Diagnostic Radiopharmaceutical Solutions
3.5.3.4 Cyclotron Based Production
3.5.3.5 Neurological Applications
3.5.4 Threat
3.5.4.1 Shutdown Of Nuclear Reactors To Impact Production Of Radioisotopes
3.6 Winning Imperatives
3.6.1 Investments On New Radioisotopes And Novel Applications
3.6.2 Shift Towards Leu-Based Mo-99 Production
3.7 Burning Issues
3.7.1 High Cost Of Pet Cameras
3.7.2 Shortage In Supply Of Technetium-99m
3.8 Regulatory Affairs
3.8.1 Germany
3.8.1.1 German Medicinal Products Act (AMG)
3.8.1.2 Amendments To The German Medicinal Products Act (AMG)
3.8.2 France
3.8.2.1 Agence Française De La Securité Sanitaire Des Produits De La Santé (AFSSAPS)
3.8.3 U.K.
3.8.3.1 The Medicines And Healthcare Products Regulatory Agency (MHRA)
3.8.4 Spain
3.8.5 Italy
3.8.5.1 The Italian Pharmaceutical Agency (AIFA)
3.8.6 Russia
3.8.6.1 The Federal Law
3.9 Market Share Analysis
3.9.1 European Radiopharmaceuticals Market
3.9.1.1 Germany
3.9.1.2 France
3.9.1.3 Italy
3.9.1.4 Spain
3.9.1.5 U.K.
3.9.1.6 Switzerland
3.9.1.7 Russia
3.9.2 Enriched Stable Isotope Market

4 European Radiopharmaceuticals Market, By Isotope
4.1 Introduction
4.2 Diagnostic Market
4.2.1 Opportunity Matrix
4.2.2 Single-Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals
4.2.2.1 Technetium-99m (Tc-99m)
4.2.2.1.1 Tc-99m To Decide Growth Trend Of Spect Radioisotopes
4.2.2.1.2 Factors Affecting Technetium-99m Market
4.2.2.1.2.1 Technetium Can Combine With 31 Different Carrier Molecules
4.2.2.1.2.2 Lack Of Availability Of Technetium
4.2.2.2 Thallium-201 (Tl-201)
4.2.2.2.1 Tl-201 Is A Potential Substitute For Tc-99m
4.2.2.3 Gallium-67 (Ga-67)
4.2.2.3.1 Fluorine-18 (PET) Might Seize Ga-67 (SPECT) Market Share In The Near Future
4.2.2.4 Iodine (I-123)
4.2.2.5 Others
4.2.3 Positron-Emission Tomography (PET) Radiopharmaceuticals
4.2.3.1 Fluorine-18
4.2.3.1.1 FDG
4.2.3.1.2 Florbetapir
4.2.3.1.3 Factors Affecting Fluorine-18 Market
4.2.3.1.3.1 Rise In Pet Procedures Increases Demand For FDG
4.2.3.1.3.2 High Generation Costs Of FDG
4.2.3.1.3.3 Need For Speedy & Efficient Transportation
4.2.3.2 Rubidium-82 (Rb-82)
4.2.3.3 Others
4.3 Therapeutic Isotopes
4.3.1 Opportunity Matrix
4.3.2 Beta Emitters
4.3.2.1 Iodine-131 (I-131)
4.3.2.2 Yttrium-90 (Y-90)
4.3.2.2.1 Y-90 Market Influenced By Popularity Of Nordion’s Therasphere
4.3.2.3 Samarium-153 (Sm-153)
4.3.2.4 Rhenium-186 (Re-186)
4.3.2.5 Lutetium-177 (Lu-177)
4.3.2.5.1 Lu-177 Is A Potential Treatment Option For Neuroendocrine Cancer
4.3.2.6 Others
4.3.2.6.1 Re-188 And P-33 Are Notable Promising Isotope
4.3.3 Alpha Emitters
4.3.3.1 Radium-223 (Ra-223) & Alpharadin
4.3.3.1.1 Successful Completion Of Phase Iii Trials In Men With Bone Metastases From CRPC
4.3.3.1.2 First In-Class Alpha Pharmaceutical
4.3.3.1.3 Alpharadin Is Advantageous Over Taxotere, Beta-Therapy And Brachytherapy
4.3.3.1.4 Success Of Alpharadin
4.3.3.1.5 Porter’s Five Forces Analysis
4.3.3.1.6 SWOT Analysis
4.3.3.2 Actinium-225 (Ac-225)
4.3.3.3 Lead-212 (Pb-212)/Bismuth-212 (Bi-212)
4.3.3.4 Astatine-211 (At-211)
4.3.3.5 Radium-224 (Ra-224)
4.3.3.6 Thorium-227 (Th-227)
4.3.4 Brachytherapy
4.3.4.1 Cesium-131
4.3.4.2 Iodine-125
4.3.4.3 Palladium-103
4.3.4.4 Iridium-192
4.3.4.5 Others

5 European Radiopharmaceuticals Market,By Application/Indication
5.1 Introduction
5.2 Diagnostic Application
5.2.1 Spect
5.2.1.1 Cardiology
5.2.1.2 Lymphoma
5.2.1.3 Thyroid
5.2.1.4 Neurology
5.2.1.4.1 Alzheimer’s, Dementia, And Parkinson’s Disease Driving Growth Of The Neurology
Spect Market
5.2.1.5 Others
5.2.2 Pet
5.2.2.1 Oncology
5.2.2.1.1 FDG F-18 Has Become A Gold Standard For Oncology Diagnosis Using Pet Scan
5.2.2.2 Cardiology
5.2.2.3 Neurology
5.2.2.4 Others
5.3 Therapeutic Application
5.3.1 Thyroid
5.3.2 Bone Metastasis
5.3.3 Lymphoma
5.3.4 Endocrine Tumors
5.3.5 Others

6 European Enriched Stable Isotopes Market
6.1 Introduction
6.2 Market Overview
6.3 Market Dynamics
6.3.1 Drivers
6.3.1.1 Stable Isotopes Are Natural In Origin & Hence Safe
6.3.1.2 Proteomics & System Biology, Major Factors To Boost The Growth Of Stables
6.3.1.3 Medical Applications Propel Stable Isotopes Market Growth
6.3.2 Restraints
6.3.2.1 Harmful Effects Of High Doses Of Stable Isotopes Affect Market Growth
6.3.2.2 High Cost Of Stables Isotope
6.4 Enriched Stables Market, By Isotope
6.4.1 Deuterium & O-18 Are Promising Isotopes
6.4.2 Carbon-13
6.4.3 Deuterium
6.4.4 Oxygen-18
6.4.5 Nitrogen-15
6.4.6 Other Stable Isotopes
6.5 Enriched Stables Market, By Application
6.5.1 Diagnostic & Therapy
6.5.2 Research
6.5.3 Pharmaceutical
6.5.4 Industrial Sector

7 Geographic Analysis
7.1 Introduction
7.2 Germany
7.3 France
7.4 U.K.
7.5 Spain
7.6 Italy
7.7 Russia
7.8 Rest Of Europe

8 Competitive Landscape
8.1 Introduction
8.2 Mergers & Acquisitions
8.3 Agreements, Partnerships, Collaborations & Joint Ventures
8.4 New Products Launch
8.5 Expansions
8.6 Other Developments

9 Company Profiles (Overview, Financials, Products & Services, Strategy, & Developments)*
9.1 Companies
9.1.1 Bracco Imaging S.P.A.
9.1.2 Cambridge Isotope Laboratories, Inc.
9.1.3 Cardinal Health, Inc.
9.1.4 Covidien, Plc
9.1.5 Eczacibasi-Monrol
9.1.6 Fujifilm Holdings Corporation
9.1.7 GE Healthcare (Subsidiary Of General Electric Company)
9.1.8 IBA Group
9.1.9 Isotec, Inc. (Sigma-Aldrich)
9.1.10 Lantheus Medical Imaging, Inc.
9.1.11 Nordion, Inc.
9.1.12 NTP Radioisotopes (Pty), Ltd.
9.1.13 Petnet Solutions, Inc. (A Subsidiary Of Siemens Medical Solutions USA, Inc.)
9.1.14 Taiyo Nippon Sanso Corporation
9.1.15 Rotem Industries, Ltd., Inc.
9.1.16 Urenco Limited
9.2 Institutes
9.2.1 Australian Nuclear Association And Technology Organization (ANSTO)
9.2.2 Institute Of Atomic Energy Polatom Radioisotope Centre
9.2.3 Institute Of Isotopes Co., Ltd.
9.2.4 Institute Of Radioelement (IRE)
*Details On Financials, Product & Services, Strategy, & Developments Might Not Be Captured In Case Of Unlisted Companies.

List Of Tables (133 Tables)

Table 1 Europe: Radiopharmaceutical Diagnostic Market,By Technology, 2010 – 2017 ($Million)
Table 2 Europe: Radiopharmaceutical Diagnostic Market,By Technology, 2010 – 2017 ($Million)
Table 3 Europe: Spect Radiopharmaceuticals Market, By Isotope,2010 – 2017 ($Million)
Table 4 Europe: Spect Radiopharmaceuticals Market, By Country, 2010 – 2017 ($Million)
Table 5 Indications Diagnosed By Tc-99m
Table 6 Europe: Tc-99m Market, By Country, 2010 – 2017 ($Million)
Table 7 Europe: Tl-201 Market, By Country, 2010 – 2017 ($Million)
Table 8 Europe: Ga-67 Market, By Country, 2010 – 2017 ($Million)
Table 9 Europe: I-123 Market, By Country, 2010 – 2017 ($Million)
Table 10 Europe: Other Radiopharmaceuticals Market, By Country, 2010 – 2017 ($Million)
Table 11 Europe: Pet Radiopharmaceuticals Market, By Isotope,2010 – 2017 ($Million)
Table 12 Europe: Pet Radiopharmaceuticals Market, By Country,2010 – 2017 ($Million)
Table 13 Europe: F-18 Market, By Country, 2010 – 2017 ($Million)
Table 14 Europe: Rb-82 Market, By Country, 2010 – 2017 ($Million)
Table 15 Europe: Other Pet Radiopharmaceuticals Market, By Country, 2010 – 2017 ($Million)
Table 16 Europe: Radiopharmaceutical Market, By Therapy,2010 – 2017 ($Million)
Table 17 Europe: Beta Emitter Radiopharmaceuticals Market,By Isotope, 2010 – 2017 ($Million)
Table 18 Europe: Beta Emitter Radiopharmaceuticals Market,By Country, 2010 – 2017 ($Million)
Table 19 Europe: I-131 Market, By Country, 2010 – 2017 ($Million)
Table 20 Europe: Y-90 Market, By Country, 2010 – 2017 ($Million)
Table 21 Europe: Sm-153 Market, By Country, 2010 – 2017 ($Million)
Table 22 Europe: Re-186 Market, By Country, 2010 – 2017 ($Million)
Table 23 Europe: Lu-177 Market, By Country, 2010 – 2017 ($Million)
Table 24 Europe: Other Beta Emitters Market, By Country,2010 – 2017 ($Million)
Table 25 Alpha Emitters Vs Beta Emitters
Table 26 Radiopharmaceuticals Characteristics & Dose Delivery Over Time
Table 27 Europe: Brachytherapy Market, By Isotope,2010 – 2017 ($Million)
Table 28 Europe: Brachytherapy Market, By Country,2010 – 2017 ($Million)
Table 29 Europe: Cs-131 Market, By Country, 2010 – 2017 ($Million)
Table 30 Europe: I-125 Market, By Country, 2010 – 2017 ($Million)
Table 31 Europe: Pd-103 Market, By Country, 2010 – 2017 ($Million)
Table 32 Europe: Ir-192 Market, By Country, 2010 – 2017 ($Million)
Table 33 Europe: Other Brachytherapy Market, By Country,2010 – 2017 ($Million)
Table 34 Europe: Spect Application Market, 2010 – 2017 ($Million)
Table 35 Europe: Cardiology Spect Market, By Country,2010 – 2017 ($Million)
Table 36 Europe: Lymphoma Spect Market, By Country,2010 – 2017 ($Million)
Table 37 Europe: Thyroid Spect Market, By Country,2010 – 2017 ($Million)
Table 38 Europe: Neurology Spect Market, By Country,2010 – 2017 ($Million)
Table 39 Europe: Other Spect Applications Market, By Country,2010 – 2017 ($Million)
Table 40 Europe: Pet Application Market, 2010 – 2017 ($Million)
Table 41 Europe: Oncology Pet Market, By Country,2010 – 2017 ($Million)
Table 42 Europe: Cardiology Pet Market, By Country,2010 – 2017 ($Million)
Table 43 Europe: Neurology Pet Market, By Country,2010 – 2017 ($Million)
Table 44 Europe: Other Pet Applications Market, By Country,2010 – 2017 ($Million)
Table 45 Europe: Radiopharmaceutical Therapeutic Application Market, 2010 – 2017 ($Million)
Table 46 Europe: Radiopharmaceutical Therapeutic Application Market, By Country, 2010 – 2017 ($Million)
Table 47 Europe: Radiopharmaceutical Thyroid Application Market,By Country, 2010 – 2017 ($Million)
Table 48 Europe: Radiopharmaceutical Bone Metastasis Application Market, By Country, 2010 – 2017 ($Million)
Table 49 Europe: Radiopharmaceutical Lymphoma Application Market, By Country, 2010 – 2017 ($Million)
Table 50 Europe: Radiopharmaceutical Endocrine Application Market, By Country, 2010 – 2017 ($Million)
Table 51 Europe: Radiopharmaceutical Other Applications Market,By Country, 2010 – 2017 ($Million)
Table 52 Europe: Stable Isotope Market, 2010 – 2017 ($Million)
Table 53 Europe: Stable Isotope Market, By Country,2010 – 2017 ($Million)
Table 54 Europe: Carbon Stable Isotope Market, By Country,2010 – 2017 ($Million)
Table 55 Europe: Deuterium Stable Isotope Market, By Country,2010 – 2017 ($Million)
Table 56 Europe: Oxygen Stable Isotope Market, By Country,2010 – 2017 ($Million)
Table 57 Europe: Nitrogen Stable Isotope Market, By Country,2010 – 2017 ($Million)
Table 58 Europe: Other Stable Isotope Market, By Country,2010 – 2017 ($Million)
Table 59 Europe: Enriched Stable Isotope Market, By Application,2010 – 2017 ($Million)
Table 60 Europe: Stable Isotopes Market For Diagnostic & Therapeutic Applications, By Country, 2010 – 2017 ($Million)
Table 61 Europe: Stable Isotopes Market For Research Applications, By Country, 2010 – 2017 ($Million)
Table 62 Europe: Stable Isotopes Market For Pharmaceutical Applications, By Country, 2010 – 2017 ($Million)
Table 63 Europe: Stable Isotopes Market For Industrial Applications, By Country, 2010 – 2017 ($Million)
Table 64 Germany: Spect Radiopharmaceutical Market, By Isotope,2010 – 2017 ($Million)
Table 65 Germany: Pet Radiopharmaceutical Market, By Isotope,2010 – 2017 ($Million)
Table 66 Germany: Radiopharmaceutical Market, By Therapy,|2010 – 2017 ($Million)
Table 67 Germany: Beta Emitter Market, By Isotope,2010 – 2017 ($Million)
Table 68 Germany: Brachytherapy Market, By Isotope,2010 – 2017 ($Million)
Table 69 Germany: Stable Isotope Market, 2010 – 2017 ($Million)
Table 70 France: Spect Radiopharmaceutical Market, By Isotope,2010 – 2017 ($Million)
Table 71 France: Pet Radiopharmaceutical Market, By Isotope,2010 – 2017 ($Million)
Table 72 France: Radiopharmaceutical Market, By Therapy,2010 – 2017 ($Million)
Table 73 France: Beta Emitter Market, By Isotope,2010 – 2017 ($Million)
Table 74 France: Brachytherapy Market, By Isotope,2010 – 2017 ($Million)
Table 75 France: Stable Isotope Market, 2010 – 2017 ($Million)
Table 76 U.K.: Spect Radiopharmaceutical Market, By Isotope,2010 – 2017 ($Million)
Table 77 U.K.: Pet Radiopharmaceutical Market, By Isotope,2010 – 2017 ($Million)
Table 78 U.K.: Radiopharmaceutical Market, By Therapy,2010 – 2017 ($Million)
Table 79 U.K.: Beta Emitter Market, By Isotope, 2010 – 2017 ($Million)
Table 80 U.K.: Brachytherapy Market, By Isotope, 2010 – 2017 ($Million)
Table 81 U.K.: Stable Isotope Market, 2010 – 2017 ($Million)
Table 82 Spain: Spect Radiopharmaceutical Market, By Isotope,2010 – 2017 ($Million)
Table 83 Spain: Pet Radiopharmaceutical Market, By Isotope,2010 – 2017 ($Million)
Table 84 Spain: Radiopharmaceutical Market, By Therapy,2010 – 2017 ($Million)
Table 85 Spain: Beta Emitter Market, By Isotope, 2010 – 2017 ($Million)
Table 86 Spain: Brachytherapy Market, By Isotope,2010 – 2017 ($Million)
Table 87 Spain: Stable Isotope Market, 2010 – 2017 ($Million)
Table 88 Italy: Spect Radiopharmaceutical Market, By Isotope,2010 – 2017 ($Million)
Table 89 Italy: Pet Radiopharmaceutical Market, By Isotope,2010 – 2017 ($Million)
Table 90 Italy: Radiopharmaceutical Market, By Therapy,2010 – 2017 ($Million)
Table 91 Italy: Beta Emitter Market, By Isotope, 2010 – 2017 ($Million)
Table 92 Italy: Brachytherapy Market, By Isotope,2010 – 2017 ($Million)
Table 93 Italy: Stable Isotope Market, 2010 – 2017 ($Million)
Table 94 Russia: Spect Radiopharmaceutical Market, By Isotope,2010 – 2017 ($Million)
Table 95 Russia: Pet Radiopharmaceutical Market, By Isotope,2010 – 2017 ($Million)
Table 96 Russia: Radiopharmaceutical Market, By Therapy,2010 – 2017 ($Million)
Table 97 Russia: Beta Emitter Market, By Isotope,2010 – 2017 ($Million)
Table 98 Russia: Brachytherapy Market, By Isotope,2010 – 2017 ($Million)
Table 99 Russia: Stable Isotope Market, 2010 – 2017 ($Million)
Table 100 Roe: Spect Radiopharmaceutical Market, By Isotope,2010 – 2017 ($Million)
Table 101 Roe: Pet Radiopharmaceutical Market, By Isotope,2010 – 2017 ($Million)
Table 102 Roe: Radiopharmaceutical Market, By Therapy,2010 – 2017 ($Million)
Table 103 Roe: Beta Emitter Market, By Isotope, 2010 – 2017 ($Million)
Table 104 Roe: Brachytherapy Market, By Isotope, 2010 – 2017 ($Million)
Table 105 Roe: Stable Isotope Market, 2010 – 2017 ($Million)
Table 106 Mergers & Acquisitions, 2010 – 2012
Table 107 Agreements, Partnerships, Collaborations & Joint Ventures, 2010 – 2013
Table 108 New Products Launch, 2010 –2013
Table 109 Expansions, 2010 –2012
Table 110 Other Developments, 2010 – 2012
Table 111 Cambridge Isotope Laboratories Inc.: Total Revenue,By Segment, 2010 – 2012 ($Million)
Table 112 Cambridge Isotope Laboratories Inc.: Total Revenue,By Geography, 2010 – 2012 ($Million)
Table 113 Cardinal Health, Inc.: Total Revenue, By Segment,2010 – 2012 ($Million)
Table 114 Cardinal Health, Inc.: Total Revenue, By Geography,2010 – 2012 ($Million)
Table 115 Covidien, Plc: Total Revenue And R&D Expenditure,2010 – 2012 ($Million)
Table 116 Covidien, Plc: Total Revenue, By Segment,2010 – 2012 ($Million)
Table 117 Covidien, Plc: Total Revenue, By Geography,2010 – 2012 ($Million)
Table 118 Fujifilm Holdings Corp: Total Revenue, By Segment,2010 – 2012 ($Million)
Table 119 Fujifilm Holdings Corp: Total Revenue, By Geography,2010 – 2012 ($Million)
Table 120 General Electric Company: Total Revenue, By Segment,2009 – 2011 ($Billion)
Table 121 General Electric Company: Total Revenue, By Geography,2009 – 2011 ($Billion)
Table 122 Iba Group: Market Revenue, By Segment,2009 – 2011 ($Million)
Table 123 Iba Group: Total Revenue, By Geography,2009 – 2011 ($Million)
Table 124 Isotec Inc.: Total Revenue, By Segment, 2009 – 2011 ($Million)
Table 125 Isotec Inc.: Total Revenue, By Geography,2009 – 2011 ($Million)
Table 126 Lantheus: Total Revenue, By Segment, 2009 – 2011 ($Million)
Table 127 Lantheus: Total Revenue, By Geography,2009 – 2011 ($Million)
Table 128 Nordion, Inc.: Total Revenue, By Segment,2010 – 2012 ($Million)
Table 129 Nordion, Inc.: Total Revenue, By Geography, 2010 – 2017
Table 130 Siemens Ag: Total Revenue And R&D Expenses,2010 – 2012 ($Million)
Table 131 Siemens Ag: Total Revenue, By Segment, 2010 – 2012 ($Million)
Table 132 Siemens Ag: Total Revenue, By Geography,2010 – 2012 ($Million)
Table 133 Taiyo Nippon Sanso, Corp.: Total Revenue, By Geography,2010 – 2012 ($Million)

List Of Figures (35 Figures)

Figure 1 Europe: Radiopharmaceuticals Market, By Segment, 2010 – 2017
Figure 2 Europe: Radiopharmaceuticals Market, By Country, 2012 ($Million)
Figure 3 Europe: Stable Isotopes Market, 2012 – 2017 ($Million)
Figure 4 Evolution Of Radiopharmaceuticals
Figure 5 Radiopharmaceuticals Market Segmentation
Figure 6 Enriched Stable Isotopes Market Segmentation
Figure 7 Market Dynamics
Figure 8 European Radiopharmaceuticals: Market Share Analysis, By Key Players, 2012
Figure 9 Germany: Radiopharmaceuticals Market Share Analysis, By Key Player, 2012
Figure 10 France: Radiopharmaceuticals Market Share Analysis, By Key Player, 2012
Figure 11 Italy: Radiopharmaceuticals Market Share Analysis, By Key Player, 2012
Figure 12 Spain: Radiopharmaceuticals Market Share Analysis, By Key Player, 2012
Figure 13 U.K.: Radiopharmaceuticals Market Share Analysis, By Key Player, 2012
Figure 14 Switzerland: Radiopharmaceuticals Market Share Analysis, By Key Players, 2012
Figure 15 European Enriched Stable Isotope: Market Share Analysis, By Key Players, 2012
Figure 16 Opportunity Matrix: European Diagnostic Radiopharmaceuticals Market (2012)
Figure 17 Spect Radiopharmaceuticals Market Share (2012)
Figure 18 Pet Radiopharmaceuticals Market Share (2012)
Figure 19 Opportunity Matrix: European Therapeutic Radiopharmaceuticals Market (2012)
Figure 20 Ra-223 Decay Chain
Figure 21 Porter’s Five Forces Analysis For Alpharadin
Figure 22 SWOT Analysis Of Alpharadin
Figure 23 Diagnostic Radiopharmaceuticals Market, By Indication (2012)
Figure 24 Key Growth Strategies, 2010 –2013
Figure 25 Cambridge Isotope Laboratories Inc.: Total Revenue And R&D Expenses, 2010 – 2012 ($Billion)
Figure 26 Cardinal Health, Inc.: Total Revenue, 2010 – 2012 ($Billion)
Figure 27 Covidien, Plc: Radiopharmaceuticals Revenue, 2010 – 2012 ($Million)
Figure 28 Fujifilm Holdings Corp: Total Revenue And R&D Expenditure, 2010 – 2012 ($Billion)
Figure 29 General Electric Company: Total Revenue And R&D Expenses, 2009 – 2011 ($Billion)
Figure 30 IBA Group: Total Market Revenue, 2009 – 2011 ($Million)
Figure 31 Isotec Inc.: Total Revenue And R&D Expenses, 2009 – 2011 ($Billion)
Figure 32 Lantheus: Total Revenue And R&D Expenses, 2009 – 2011 ($Million)
Figure 33 Nordion, Inc.: Total Market Revenue, 2010 – 2012 ($Million)
Figure 34 Taiyo Nippon Sanso, Corp.: Total Revenue And R&D Expenditure, 2010 – 2012 ($Billion)
Figure 35 Urenco Limited: Total Market Revenue, 2009 – 2011 ($Billion)

FEATURED COMPANIES

  • Bracco Imaging SPA
  • Cardinal Health, Inc
  • Covidien, Plc
  • Eczacibasi-Monrol
  • IBA Group
  • Nordion, Inc
  • MORE

The therapy market is predominantly driven by its oncologic applications. Since conventional treatment procedures of cancer, surgery and chemotherapy have significant side effects, radioisotopes are being preferred by medical practitioners due to minimum or no side effects. The radiopharmaceutical therapy market is expected to grow significantly with the launch of the much-desired Alpharadin (Ra-223) in the near future. This isotope has tremendous potential to take up market share of beta emitters and brachytherapy.

Germany accounted for the largest market share of the European nuclear medicine market, followed by France in 2012. Major players in the radiopharmaceuticals market are Covidien, Plc, GE Healthcare, IBA Group, Lantheus Medical Imaging, Inc., Nordion, Inc., and Siemens Healthcare (PETNET).

The stable isotopes market is dominated by deuterium (D2), oxygen-18 (O-18), carbon-13 (C-13), and nitrogen-15 (N-15). It has major applications in research, pharmaceuticals, diagnostic and therapy, and the industrial sector. The diagnostic and therapy market accounted for the maximum share of the stable isotopes market. The European stable isotopes market was valued at close to $25.0 million in 2012, and is estimated to grow at a CAGR of more than 8.0% by 2017. The stable isotopes market was led by two players - Cambridge Isotope Laboratories (CIL) and Sigma Aldrich - in 2012; they jointly contributed more than 50% to the European revenue.

- Bracco Imaging SPA
- Cambridge Isotope Laboratories, Inc
- Cardinal Health, Inc
- Covidien, Plc
- Eczacibasi-Monrol
- Fujifilm Holdings Corporation
- GE Healthcare (Subsidiary Of General Electric Company)
- IBA Group
- Isotec, Inc (Sigma-Aldrich)
- Lantheus Medical Imaging, Inc
- NTP Radioisotopes (Pty), Ltd
- Nordion, Inc
- Petnet Solutions, Inc (A Subsidiary Of Siemens Medical Solutions USA, Inc)
- Rotem Industries, Ltd, Inc
- Taiyo Nippon Sanso Corporation
- Urenco Limited

Institutes Mentioned in the Report

- Australian Nuclear Association And Technology Organization (ANSTO)
- Institute Of Atomic Energy Polatom Radioisotope Centre
- Institute Of Isotopes Co, Ltd
- Institute Of Radioelement (IRE)

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos